Abbott Laboratories Q2 2026 Sales Grow 4.8%, EPS Beats
Abbott Laboratories (ABT) reported Q2 2026 comparable sales growth of 4.8% and adjusted EPS of $1.31. Chairman and CEO Robert Ford said results marked an acceleration from the prior two quarters. The company reaffirmed its full-year guidance.
Key Numbers
Abbott Laboratories (NYSE:ABT) reported second-quarter 2026 comparable sales growth of 4.8% and adjusted earnings per share (EPS) of $1.31. Chairman and CEO Robert Ford described the results as an acceleration from the prior two quarters.
Key Financial Results
| Metric | Value |
|---|---|
| Comparable Sales Growth | 4.8% |
| Adjusted EPS | $1.31 |
The company did not provide total revenue or net income figures in the summary.
Highlights from the Call
CEO Robert Ford emphasized that the results reflect improving momentum compared to the first two quarters of the year.
Future Guidance
Abbott reaffirmed its full-year 2026 guidance, though specific numerical targets were not disclosed in the summary.
Stock Impact
No immediate stock price reaction was reported.
What This Means for Investors
The results suggest steady performance and gradual improvement, with reaffirmed guidance reinforcing management's confidence in achieving annual targets.
Frequently Asked Questions
Found this useful? Share it